AlphAIAlphAI — Financial news for AI agents
Stock TitanMAR 203 min read$NAII

NAII SEC Filings - Naturl Alt Intl 10-K, 10-Q, 8-K Forms

This page provides comprehensive access to Naturl Alt Intl (NAII) SEC filings, including 10-K, 10-Q, and 8-K forms, crucial for investors in the nutritional supplements sector. It highlights specific events such as CEO stock purchases, quarterly financial performance, and amendments to credit facilities. The platform also offers AI-powered summaries to help users quickly grasp key information from these regulatory documents.

Original reporting
Stock Titan
Published Mar 20, 2026, 8:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 20, 2026, 9:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$NAII
Neutral
medium confidence
Mentioned
$NAII
Relevance
6/10
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$NAIINeutralLow
01

Why it matters

The filings suggest stability with no immediate red flags; however, insider activities and amendments warrant attention for potential strategic moves.

02

Market read

While the filings provide valuable insights, their direct impact on stock price appears limited in the short term.

03

What to watch

Market reaction could be influenced by broader economic conditions or sector trends not captured in filings.

Relevance 6/10Timing: Moderate; filings are recent but market reaction may be delayed.

Background

Naturl Alt Intl (NAII) is a nutritional supplements company with recent SEC filings providing detailed financial and operational disclosures.

Company-level read

Ticker impact

$NAIINeutralMedium confidence
Context

Primary focus due to recent SEC filings and insider activities.

Expected impact

Limited immediate impact; potential for moderate positive movement if financials are favorable.

Evidence & confidence

Financial data from filings is recent but requires further market context for precise impact assessment.

Market effects

Sector

Potential sector-wide cautiousness due to financial updates.

Regional

Minimal; company operates primarily in the U.S.

Global

Low; company has limited international exposure.

Counterpoint

What could challenge this read

Some investors may interpret insider stock purchases as confidence, potentially leading to short-term buying opportunities.

Key entities

  • Company
    Naturl Alt Intl

    A company operating in the nutritional supplements sector.

  • Insider Activity
    CEO Stock Purchases

    Insider buying indicating possible confidence in future prospects.

  • Financial Event
    Credit Facility Amendments

    Changes to credit agreements that may affect liquidity or leverage.

Read at source← All news

Related articles

OCT 8
Low

Nous Research $90M Raise: NVIDIA’s Dual Bet Reveals the Compute Landlord Strategy

NVIDIA is investing in both proprietary and open-source AI models, including a $90M Series B round for Nous Research, valuing it at $1.5B. Nous claims its Hermes 4.3 model outperforms GPT-4o in key metrics, but lacks independent verification. The company aims to compete with lower pricing, offering $0.30 per million tokens compared to competitors' higher rates. NVIDIA's strategy ensures its hardware remains central to AI infrastructure regardless of the winning model architecture.

finance.yahoo.com1 min
OCT 8
$BHVNMed

Biohaven Licenses IgG Degrader Portfolio To Ono Pharma In Key Asian Markets

Biohaven (BHVN) has licensed its IgG degrader portfolio to Ono Pharma for Asian markets, including Japan and South Korea. The deal includes up to $100M in payments, with Biohaven retaining rights outside these regions. The portfolio, led by BHV-1300 in Phase 3 trials for Graves' disease, aims to treat autoimmune disorders. Biohaven's stock closed at $11.88, up 1.18% in pre-market trading.

rttnews.com2 min
OCT 8
$BAMed

NASA to pump hundreds of millions more tax dollars into troubled Boeing Starliner

NASA plans to invest $359 million more in Boeing's Starliner capsule for ISS missions, despite technical issues. The agency aims to send an unmanned Starliner to the ISS by late 2027, with a manned mission possible in 2028. The ISS is set to retire by 2030. SpaceX's Dragon Crew is noted as a cheaper, more reliable alternative. NASA insists on having two providers for ISS missions. Dr. Ken Kremer, a space expert, highlights the high stakes of maintaining a presence in low Earth orbit.

cbs12.com2 min
OCT 8
$TWSTMed

Jefferies initiates Twist Bioscience stock at Hold on valuation

Jefferies initiated coverage on Twist Bioscience (TWST) with a Hold rating and $150 price target, citing premium valuation. The stock trades at $155.65 after a 391% YTD surge. Jefferies notes its market differentiation and AI-driven growth, but warns of high valuation expectations. TWST partners with Eli Lilly's TuneLab for AI/ML drug discovery, while BWS Financial rates it Sell, and Guggenheim reiterates Buy.

investing.com2 min